FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151969933> ?p ?o ?g. }

• W2151969933 endingPage "212.e1" @default.
• W2151969933 startingPage "205" @default.
• W2151969933 abstract "The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) is evaluating the potential benefit for reduction in major cardiovascular (CV) events from the addition of ezetimibe versus placebo to 40 mg/d of simvastatin therapy in patients who present with acute coronary syndromes and have low-density lipoprotein cholesterol (LDL-C) ≤125 mg/dL. The primary composite end point is CV death, nonfatal myocardial infarction (MI), nonfatal stroke, rehospitalization for unstable angina (UA), and coronary revascularization (≥30 days postrandomization). The simvastatin monotherapy arm’s LDL-C target is <70 mg/dL. Ezetimibe was assumed to further lower LDL-C by 15 mg/dL and produce an estimated ~8% to 9% treatment effect. The targeted number of events is 5,250. We enrolled 18,144 patients with either ST-segment elevation MI (STEMI, n = 5,192) or UA/non–ST-segment elevation MI (UA/NSTEMI, n = 12,952) from October 2005 to July 2010. Western Europe (40%) and North America (38%) were the leading enrolling regions. The STEMI cohort was younger and had a higher percentage of patients naive to lipid-lowering treatment compared with the UA/NSTEMI cohort. The UA/NSTEMI group had a higher prevalence of diabetes, hypertension, and prior MI. Median LDL-C at entry was 100 mg/dL for STEMI and 93 mg/dL for UA/NSTEMI patients. This trial is evaluating LDL-C lowering beyond previously targeted LDL-C levels. The results depend on achieving the desired separation of LDL-C with ezetimibe and on the assumption that ezetimibe’s lowering of LDL-C will have similar event reduction efficacy as the LDL-C lowering from a statin. The results could affect future therapies and guidelines." @default.
• W2151969933 created "2016-06-24" @default.
• W2151969933 creator A5026602252 @default.
• W2151969933 creator A5033936422 @default.
• W2151969933 creator A5043533532 @default.
• W2151969933 creator A5045665978 @default.
• W2151969933 creator A5060829829 @default.
• W2151969933 creator A5064339118 @default.
• W2151969933 creator A5078336416 @default.
• W2151969933 creator A5081871633 @default.
• W2151969933 creator A5082493414 @default.
• W2151969933 creator A5090460841 @default.
• W2151969933 date "2014-08-01" @default.
• W2151969933 modified "2023-10-16" @default.
• W2151969933 title "Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population" @default.
• W2151969933 cites W1430649507 @default.
• W2151969933 cites W156853490 @default.
• W2151969933 cites W1964532888 @default.
• W2151969933 cites W1977399475 @default.
• W2151969933 cites W1981193135 @default.
• W2151969933 cites W198828404 @default.
• W2151969933 cites W2018711158 @default.
• W2151969933 cites W2025690892 @default.
• W2151969933 cites W2040462758 @default.
• W2151969933 cites W2052094004 @default.
• W2151969933 cites W2100800328 @default.
• W2151969933 cites W2106343349 @default.
• W2151969933 cites W2111385165 @default.
• W2151969933 cites W2118825330 @default.
• W2151969933 cites W2120289695 @default.
• W2151969933 cites W2134120087 @default.
• W2151969933 cites W2139168645 @default.
• W2151969933 cites W2150799450 @default.
• W2151969933 cites W2159449551 @default.
• W2151969933 cites W2164089346 @default.
• W2151969933 cites W2164324917 @default.
• W2151969933 cites W2165605025 @default.
• W2151969933 cites W2167045683 @default.
• W2151969933 cites W2187593761 @default.
• W2151969933 cites W3021659692 @default.
• W2151969933 doi "https://doi.org/10.1016/j.ahj.2014.05.004" @default.
• W2151969933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25066560" @default.
• W2151969933 hasPublicationYear "2014" @default.
• W2151969933 type Work @default.
• W2151969933 sameAs 2151969933 @default.
• W2151969933 citedByCount "90" @default.
• W2151969933 countsByYear W21519699332014 @default.
• W2151969933 countsByYear W21519699332015 @default.
• W2151969933 countsByYear W21519699332016 @default.
• W2151969933 countsByYear W21519699332017 @default.
• W2151969933 countsByYear W21519699332018 @default.
• W2151969933 countsByYear W21519699332019 @default.
• W2151969933 countsByYear W21519699332020 @default.
• W2151969933 countsByYear W21519699332021 @default.
• W2151969933 countsByYear W21519699332022 @default.
• W2151969933 crossrefType "journal-article" @default.
• W2151969933 hasAuthorship W2151969933A5026602252 @default.
• W2151969933 hasAuthorship W2151969933A5033936422 @default.
• W2151969933 hasAuthorship W2151969933A5043533532 @default.
• W2151969933 hasAuthorship W2151969933A5045665978 @default.
• W2151969933 hasAuthorship W2151969933A5060829829 @default.
• W2151969933 hasAuthorship W2151969933A5064339118 @default.
• W2151969933 hasAuthorship W2151969933A5078336416 @default.
• W2151969933 hasAuthorship W2151969933A5081871633 @default.
• W2151969933 hasAuthorship W2151969933A5082493414 @default.
• W2151969933 hasAuthorship W2151969933A5090460841 @default.
• W2151969933 hasBestOaLocation W21519699331 @default.
• W2151969933 hasConcept C126322002 @default.
• W2151969933 hasConcept C142724271 @default.
• W2151969933 hasConcept C164705383 @default.
• W2151969933 hasConcept C204787440 @default.
• W2151969933 hasConcept C27081682 @default.
• W2151969933 hasConcept C2776329913 @default.
• W2151969933 hasConcept C2776839432 @default.
• W2151969933 hasConcept C2777698277 @default.
• W2151969933 hasConcept C2777785093 @default.
• W2151969933 hasConcept C2778657065 @default.
• W2151969933 hasConcept C2908647359 @default.
• W2151969933 hasConcept C500558357 @default.
• W2151969933 hasConcept C71924100 @default.
• W2151969933 hasConcept C72563966 @default.
• W2151969933 hasConcept C99454951 @default.
• W2151969933 hasConceptScore W2151969933C126322002 @default.
• W2151969933 hasConceptScore W2151969933C142724271 @default.
• W2151969933 hasConceptScore W2151969933C164705383 @default.
• W2151969933 hasConceptScore W2151969933C204787440 @default.
• W2151969933 hasConceptScore W2151969933C27081682 @default.
• W2151969933 hasConceptScore W2151969933C2776329913 @default.
• W2151969933 hasConceptScore W2151969933C2776839432 @default.
• W2151969933 hasConceptScore W2151969933C2777698277 @default.
• W2151969933 hasConceptScore W2151969933C2777785093 @default.
• W2151969933 hasConceptScore W2151969933C2778657065 @default.
• W2151969933 hasConceptScore W2151969933C2908647359 @default.
• W2151969933 hasConceptScore W2151969933C500558357 @default.
• W2151969933 hasConceptScore W2151969933C71924100 @default.
• W2151969933 hasConceptScore W2151969933C72563966 @default.
• W2151969933 hasConceptScore W2151969933C99454951 @default.
• W2151969933 hasIssue "2" @default.

• next